Results 111 to 120 of about 37,430 (216)

POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, Volume 101, Issue 10, Page 2632-2651, October 2026.
ABSTRACT Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease.
Angela Dispenzieri
wiley   +1 more source

A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

British Journal of Haematology, EarlyView.
Runfeng Zhang, Hong Yu, Miao Chen, Xiaoqi Qin, Jie Xiao, Yun Leng, Mingzhe Zhao, Jie Yu, Chunjie Qin, Xiuju Wang, Jingcheng Zhang, Wei Wang, Wenming Chen, Yanping Ma, Rong Fu, Junling Zhuang   +15 more
wiley   +1 more source

Treatment Patterns and Clinical Outcomes Among Chinese Patients With Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Study (CHAMP‐MM)

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT The therapeutic landscape for newly diagnosed multiple myeloma (NDMM) in China has evolved significantly with wider access to novel agents, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and CD38 monoclonal antibodies.
Jian Cui, Xiaoyan Qu, Chunrui Li, Fei Li, Liye Zhong, Xiaohong Fu, Gang Liu, Lugui Qiu, Gang An   +8 more
wiley   +1 more source

AUTOLOGOUS STEM CELL TRANSPLANTATION EXPERIENCE IN B-ALL DEVELOPING DURING MAINTENANCE LENALIDOMIDE TREATMENT:CASE REPORT

Hematology, Transfusion and Cell Therapy
Case report: Introduction: Secondary leukemias that occur after chemotherapy are mostly myelodysplastic syndrome and acute myeloid leukemias.With the recent increased use of immunomodulatory (IMID) drugs (pomalidomide, thalidomide and lenalidomide); It ...
Kemal Fıdan, Gülşah Akyol, Ali Ünal, Muzaffer Keklik, Nursima Çukadar   +4 more
doaj   +1 more source

Multiple Primary Malignancies Involving Papillary Thyroid Carcinoma: A Three‐Case Series

Clinical Case Reports, Volume 14, Issue 10, October 2026.
Patients with papillary thyroid carcinoma may develop distinct additional primary malignancies. New lesions or lymphadenopathy should not be presumed to represent metastatic PTC without tissue confirmation, emphasizing accurate diagnosis, multidisciplinary evaluation, and individualized treatment.
Katayoon Ghasemi, Amirhossein Rezaei Latifi, Mohammad Salari   +2 more
wiley   +1 more source

Banding Karyotyping From Peripheral Blood Is a Useful Method for the Diagnostic Workup of Myelodysplastic Neoplasia and CMML

Genes, Chromosomes and Cancer, Volume 65, Issue 10, October 2026.
ABSTRACT This retrospective study involving 155 patients from the Düsseldorf MDS Registry compared cytogenetic banding from peripheral blood (PB) and bone marrow (BM) in patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).
Cornelia Heusler, Barbara Hildebrandt, Felicitas Schulz, Kathrin Nachtkamp, Corinna Strupp, Valerie Flatten, Sascha Dietrich, Norbert Gattermann, Ulrich Germing   +8 more
wiley   +1 more source

Generalizable Strategies for the Synthesis of Cereblon‐Recruiting PROTAC Prodrugs

Angewandte Chemie, Volume 138, Issue 40, 28 September 2026.
Cereblon‐recruiting PROTACs remain challenging to derivatize for prodrug‐based delivery. In this study, three complementary conjugation strategies enabled the efficient synthesis of cleavable PROTAC prodrugs with tunable release kinetics that can be incorporated into a library of PEGylated constructs and bottlebrush prodrugs.
Aiden X. Wang, Bin Liu, Elise M. Ackerman, Yichen Xiang, Hung V.‐T. Nguyen, Yivan Jiang, Angela N. Koehler, Jeremiah A. Johnson   +7 more
wiley   +2 more sources

Plerixafor and G‐CSF Versus Placebo and G‐CSF in Moderately Mobilizing Patients With Multiple Myeloma to Optimize Hematopoietic Stem Cell Collection Results (OPTIMIZE)

Journal of Clinical Apheresis, Volume 41, Issue 5, October 2026.
ABSTRACT Efficient collection of hematopoietic progenitor cells (HPCs) is essential for autologous stem cell transplantation (ASCT) in multiple myeloma (MM). Although plerixafor is routinely used in poor mobilizers, its role in patients with intermediate mobilization capacity remains unclear.
Worel Nina, Schreder Martin, Tanzmann Andreas, Kurz Martin, Huber‐Kraßnitzer Bianca, Neumeister Peter, Rosskopf Konrad, Sareban Nazanin, Branka Manuela, Kolovratova Vera, Oesterreicher Sophia, Koerbler Beatrix, Kitzweger Elvira, Ruckser Reinhard, Rabitsch Werner, Agis Hermine, Krauth Maria, Greinix Hildegard T.   +17 more
wiley   +1 more source

The role of upfront lenalidomide maintenance for primary central nervous system lymphoma following first‐line methotrexate treatment: A retrospective study

Cancer Medicine
Background Consolidation therapy improves the duration of response among patients with primary central nervous system lymphoma (PCNSL). Lenalidomide maintenance has shown encouraging results in older patients with PCNSL.
Yan Zhang, Wei Wang, Danqing Zhao, Wei Chong, Chao Chen, Wei Zhang, Daobin Zhou   +6 more
doaj   +1 more source

A case of lenalidomide-induced hypersensitivity pneumonitis.

, 2010
BACKGROUND Lenalidomide is a new immunomodulatory drug, FDA-approved for the treatment of the 5q-myelodysplastic syndrome and refractory or relapsed multiple myeloma (MM).
Quadri F, Mazzucchelli L, Györik S, Feilchenfeldt J, Lerch E   +4 more
core   +1 more source